Company / Accounts Receivable
BIODESIX INC Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$9.0M
FY2025
5-year range
$3.7M / $9.0M
FY2021-FY2025
Trend
+5.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 4 consecutive years, from $4M in FY2021 to $9M in FY2025.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of -10.0%.
Improved from $8M to $9M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +21.3%
- 5-Year CAGR
- -10.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- BIODESIX INC's accounts receivable has grown for 4 consecutive years.
- 5-year CAGR of -10.0%, indicating a declining trend.
- In FY2025, accounts receivable increased 5.0% year-over-year.
- Peak accounts receivable was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -4.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.0M | +5.0% |
| FY2024 | $8.6M | +12.0% |
| FY2023 | $7.7M | +51.6% |
| FY2022 | $5.1M | +38.5% |
| FY2021 | $3.7M | -76.1% |
| FY2020 | $15.3M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026